Together with four other UK charities, JDRF has today launched an appeal against a NICE (National Institute for Health and Clinical Excellence) decision not to recommend the drug Lucentis for treatment of Diabetic Macular Oedema (DMO) on the NHS.
Current research indicates that ranibizumab (marketed as Lucentis) is highly effective in treating DMO and, significantly, that it meets an unmet need for patients who do not respond well to the current standard laser treatment.
JDRF supported the early development of Lucentis through our Innovative Grant programme. Further collaboration with Genentech, a biotech company based in San Francisco, and Johns Hopkins Medical School, enabled clinical research to help reveal the full therapeutic benefit of the drug for people with type 1 diabetes.
JDRF is working together with Diabetes UK, Macular Disease Society and the Royal National Institute of Blind People (RNIB) to put together an appeal to encourage NICE, the Department of Health and the drug manufacturer to ensure the drug is available to patients with Diabetic Macular Oedema on the NHS.
The charities are also urging the drug manufacturer, the Department of Health and NICE to reconsider the option of a Patient Access Scheme so that a maximum number of patients can benefit from this new sight saving treatment.
The drug offers a real step change from the currently available laser treatment. It prevents further sight loss and in many cases even improves vision. We understand that NICE must consider the cost effectiveness of any new drug. But the impact of blindness is such that NICE, the Department of Health and the drug manufacturer must work together to find a solution that prevents people losing their sight when a licensed and effective treatment is available.
Join in with the campaign
Why not join us in making a noise about NICE’s decision and how it will impact you? We need help from all people affected by type 1 diabetes and Diabetic Macular Odeoma to spread the word about out appeal in a bid to get NICE to reconsider their decision.
You can show your support by following the conversations on Twitter @JDRFUK today and tweeting your comments and using the hashtag #lucentis.
If you don’t use Twitter, become our friend by searching for JDRF UK on Facebook and join the conversation that way.